You searched for "vascularisation"

274 results found

Topical doxycycline for corneal neovascularisation

Six eyes with corneal vascularisation were treated with 1% topical doxycycline, four times a day for three weeks. The patients were reviewed at various intervals over a period of one year. The eyes selected had neovascularisation secondary to a variety...

Late stromal rejection in DALK

This case series reported on late stromal rejections in eyes after uncomplicated deep anterior lamellar keratoplasties (DALKs). Four eyes of three patients experienced episodes of isolated stromal rejection 33 to 46 months after surgically uncomplicated DALKs and a minimum of...

Comparison of treatment regimes for APROP

The authors evaluated the risk factors and treatment outcomes of various treatment options for APROP including intra-vitreal anti-VEGF injections, laser treatment and a combination of both. This was an observational study of all consecutive cases of untreated APROP from 2018-19...

Type 3 CNV and anti-VEGF

The purpose of the study was to determine the differences between aflibercept and ranibizumab in terms of their therapeutic efficacy in the treatment of Type 3 neovascularisation. The authors highlight that the dominant mechanism for Type 3 neovascularisation development is...

Intravitreal ranibizumab for the treatment of myopic CNV

The authors conducted a prospective study. Sixty-four patients (65 eyes) attended the 12-month follow-up examination. The mean patient age was 47.8 years. Fifty-five patients (86.0%) were females. All patients had pathologic myopia (a spherical equivalent of more than − 6.0...

Treat-and-extend regimen in treatment of patients with type 3 neovascularisation

Type 3 neovascularisation, also known as retinal angiomatous proliferation is a distinct subtype of neovascular AMD characterised by intraretinal neovascularisation. This retrospective study included 17 eyes diagnosed with type 3 neovascularisation who were changed from pro-re-nata (PRN) based treatment regime...

A patient report of pseudoxanthoma elasticum, angioid streaks and choroidal neovascularisation

Angioid streaks (AS) on their own do not cause many problems, with the majority of patients remaining asymptomatic [1]. However, once choroidal neovascularisation (CNV) occurs, the visual prognosis of the patient rapidly declines [2]. Treatment is imperative to try and...

Progression of myopic maculopathy after treatment

The authors report on a retrospective study carried out to evaluate long-term progression of myopic maculopathy and functional outcome in eyes treated for myopic choroidal neovascularisation (CNV) and in eyes without CNV. Fifty-four myopic eyes of 30 patients were included...

Platelet rich fibrin membrane for descemetocele

This case series described the use of a novel technique in the treatment of descemetocele. Three patients developed descemetoceles following infective keratitis with impending risk of corneal perforation. Platelet rich fibrin (PRF) membrane was prepared using 8ml of fresh venous...

ROP anti-VEGF treatment review

The purpose of this review was to consider data relating to risks and benefits of the use of anti-VEGF treatment for retinopathy of prematurity (ROP) over the past five years of 2015-2020. Ocular benefits include treatment of aggressive posterior ROP,...

Corneal crosslinking in pellucid marginal degeneration

Fourteen studies were included in this first review examining the use of corneal-crosslinking (CXL) to treat pellucid marginal degeneration (PMD). PMD is a bilateral, non-inflammatory corneal thinning disorder characterised by inferior peripheral corneal thinning 1-3mm from the limbus in the...

MicroRNA inhibits corneal neovascularisation

MicroRNAs (miR) are small non-coding RNA that target mRNA for destruction. MiR target about 30% of the protein coding genes and fine tune their expression. MiR have been shown to be involved in several cellular processes including cell cycle, tissue...